Angiomax Patent Decision, Seven Possible Approvals Mean Catalytic Year For The Medicines Co.
This article was originally published in The Pink Sheet Daily
Executive Summary
While readying an appeal to a patent ruling benefiting Hospira’s efforts to introduce an Angiomax generic, the hospital-care specialist has several drugs nearing regulatory decisions in the U.S. and Europe.